Bristol Myers Squibb Co (NYSE: BMY) faces fresh allegations in a recent lawsuit, accused of employing deceptive patents and illicit strategies to preserve its dominant position in the blood cancer drug market with Pomalyst (pomalidomide) long after it should have faced competition from generic alternative
Royal Philips (NYSE:PHG, AEX: PHIA)))) announced today that the company and certain of its US subsidiaries, including Philips Respironics, have reached an agreement to resolve all economic loss claims in the
Former Celsius (CRYPTO: CEL) CEO Alex Mashinsky faces a freeze on his banking and real estate assets amid an ongoing criminal investigation, according to court records.